Sanofi inks an alliance pact with chronic disease-focused digital therapeutics player
Over the past few years, the digital health space has been rapidly expanding and drawing the attention of Big Pharma. Now, one company has grabbed Sanofi’s attention — and sealed a deal.
New-York based DarioHealth announced it entered into a strategic alliance agreement with Sanofi’s US subsidiary in a multi-year, $30 million deal. The agreement will push Dario’s “digital therapeutics” market expansion and commercial adoption, the company said in a statement.
This is just the most recent development in the digital health space. Digital therapeutics companies like Akili with its prescription video game and Ada Health — building a diagnostics app and raising $30 million a few weeks ago — have already started to make their footprint on the space.
In short, Dario’s AI-based platform is primarily a highly personalized health management system — tying custom devices such as a glucose monitoring system, blood pressure cuff and weight scale to Dario’s mobile app — which users with diabetes, hypertension and other ailments can use to manage their conditions. And additional expansion is ongoing, with the company going into musculoskeletal pain and behavioral health after it acquired two smaller companies.
As DarioHealth president Rick Anderson told Endpoints News, part of the platform is to learn user’s routines — “would understand when to communicate to them, what they responded to, what they didn’t respond to, and the ability to adjust that communication over a period of time.” And on top of an AI engine that runs the platform, DarioHealth has been building solutions and applications and cross-integrating them into one app.
According to Anderson, that cross-integration allows for a “unified user experience.” And while the company originally went to consumers first when they got their start in 2011, DarioHealth now is looking to bring health plans and payers into the mix.
Sanofi originally reached out to Dario, Anderson said — and they have been building the relationship for the last 9-10 months. The deal is a mix between marketing and co-development: Sanofi will help promote DarioHealth’s solutions, and everything that gets developed as part of the several-year agreement will be commercialized on Dario’s platform.
Sanofi is training their market access teams around Dario’s platform, according to Anderson — and with the focus on health plans, the Sanofi deal gives them greater reach into that space.
Eventually, there may be an option to link Sanofi’s drugs into the app, according to Anderson — but that is not part of today’s announced agreement.